Pfizer Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PFIZER, and what generic alternatives to PFIZER drugs are available?
PFIZER has one hundred and ninety-five approved drugs.
There are forty-nine US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.
There are one thousand and twenty-four patent family members on PFIZER drugs in seventy countries and two hundred and sixty supplementary protection certificates in nineteen countries.
Summary for Pfizer
International Patents: | 1024 |
US Patents: | 49 |
Tradenames: | 159 |
Ingredients: | 130 |
NDAs: | 195 |
Drug Master File Entries: | 3 |
Patent Litigation for Pfizer: | See patent lawsuits for Pfizer |
PTAB Cases with Pfizer as petitioner: | See PTAB cases with Pfizer as petitioner |
Drugs and US Patents for Pfizer
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 217439-005 | Mar 7, 2024 | RX | Yes | No | 10,780,088 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | CLEOCIN T | clindamycin phosphate | GEL;TOPICAL | 050615-001 | Jan 7, 1987 | AB1 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | XELJANZ XR | tofacitinib citrate | TABLET, EXTENDED RELEASE;ORAL | 208246-002 | Dec 12, 2019 | RX | Yes | Yes | 11,253,523 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | PROCARDIA | nifedipine | CAPSULE;ORAL | 018482-002 | Jul 24, 1986 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pfizer
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pfizer | TROVAN | trovafloxacin mesylate | TABLET;ORAL | 020759-001 | Dec 18, 1997 | 5,164,402 | ⤷ Try a Trial |
Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-001 | Feb 26, 1996 | 5,200,196 | ⤷ Try a Trial |
Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-003 | Dec 28, 1999 | 4,344,949*PED | ⤷ Try a Trial |
Pfizer | ZAVZPRET | zavegepant hydrochloride | SPRAY, METERED;NASAL | 216386-001 | Mar 9, 2023 | 7,314,883 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Delayed-release Tablets | 75 mg/0.2 mg | ➤ Subscribe | 2008-11-28 |
➤ Subscribe | Extended-release Tablets | 4 mg and 8 mg | ➤ Subscribe | 2012-10-31 |
➤ Subscribe | Injection | 20 mg/mL, 2 mL and 5 mL vials | ➤ Subscribe | 2004-07-26 |
➤ Subscribe | Capsules | 5 mg and 10 mg | ➤ Subscribe | 2005-06-21 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2011-06-17 |
➤ Subscribe | Oral Suspension | 100 mg/5 mL | ➤ Subscribe | 2009-08-03 |
➤ Subscribe | Injection | 2 mg/mL, 100 mL bag | ➤ Subscribe | 2009-12-29 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Delayed-release Tablets | 50 mg/0.2 mg | ➤ Subscribe | 2009-06-29 |
➤ Subscribe | Extended-release Tablets | 11 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
➤ Subscribe | Capsules | 75 mg, 100 mg and 125 mg | ➤ Subscribe | 2019-02-04 |
➤ Subscribe | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | ➤ Subscribe | 2014-05-01 |
➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2005-12-21 |
➤ Subscribe | Injection | 2 mg/mL, 300 mL bag | ➤ Subscribe | 2009-09-01 |
➤ Subscribe | Tablets | 1 g | ➤ Subscribe | 2005-08-23 |
International Patents for Pfizer Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20170129245 | ⤷ Try a Trial |
Australia | 2006210572 | ⤷ Try a Trial |
Australia | 2014220354 | ⤷ Try a Trial |
Iceland | 7323 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pfizer Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2316456 | 1790064-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REG. NO/DATE: EU/1/14/988 20150330 |
2603514 | 19C1021 | France | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON DE VABORBACTAME, ET/OU D'UN SEL ET/OU D'UN HYDRATE DE CELUI-CI, ET DE MEROPENEME, ET/OU D'UN SEL ET/OU D'UN HYDRATE DE CELUI-CI, EN PARTICULIER DE MEROPENEME TRIHYDRATE; REGISTRATION NO/DATE: EU/1/18/1334 20181122 |
1304992 | 2013/044 | Ireland | ⤷ Try a Trial | PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322 |
0253738 | C960002 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.